drugset / Trial / NCT07071974

A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body

NCT07071974

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate relative bioavailability of BI 456906 reference formulation (Formulation A) vs. BI 456906 test formulation (Formulation B2).

Timeline

Start
2025-07-28
Primary completion
2025-10-07
Completion
2025-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Survodutide Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.